Pilot evaluation of ivacaftor for chronic bronchitis

Slides:

Advertisements

Similar presentations

COPD case finding by spirometry in high-risk customers of urban community pharmacies: A pilot study D. Castillo, R. Guayta, J. Giner, F. Burgos, C. Capdevila,

Advertisements

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Venezuela: violence, human rights, and health-care realities

Positive Expiratory Pressure for the Treatment of Acute Asthma Exacerbations: A Randomized Controlled Trial Nidhya Navanandan, MD, Monica Federico, MD,

Volume 357, Issue 9273, Pages (June 2001)

Pharmacogenetics and future drug development and delivery

Volume 143, Issue 3, Pages e1 (September 2012)

Volume 103, Issue 4, Pages (April 2009)

A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease Yoshihiro Kobashi,

R. Naseer, L.J. Buck, M. Small, M. Munavvar Respiratory Medicine CME

Is ginger effective for the treatment of irritable bowel syndrome

Edward G. Seferian, Nancy K. Henry, Mark E. Wylam Respiratory Medicine

Thank God for Richard Dawkins?

Simple versus complex COPD: implications for health-care management

COPD and asthma: the emergency is clear, now is the time for action

Author gender in The Lancet journals

COPD and asthma: the emergency is clear, now is the time for action

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,

Volume 13, Issue 3, Pages (March 2012)

Blood eosinophils as a marker of eosinophilic exacerbations in COPD

Gareth L Ackland, Maurizio Cecconi, Rupert M Pearse

Political factors behind US global AIDS programmes slow-down

Do air quality alerts benefit public health? New evidence from Canada

Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study Dr James D Chalmers, MBChB, Brian J.

Effective cross-sector collaborations create sustainability

Magnet ingestion in children—a potentially sticky issue?

Arnaud Chiolero The Lancet Public Health

Alcohol use among young adolescents in low-income and middle-income countries: a population-based study Chuanwei Ma, MSc, Pascal Bovet, MD, Lili Yang,

HIV myths should not be resuscitated

Pharmacogenetic testing in the UK clinical setting

Malebona Precious Matsoso, Jeanette Rebecca Hunter, Vishal Brijlal

Effect of development assistance on domestic health expenditures

Classification of CFTR mutation classes

Volume 143, Issue 1, Pages (January 2013)

MERS in South Korea and China: a potential outbreak threat?

Volume 362, Pages s6-s7 (December 2003)

Adrian Martineau The Lancet Respiratory Medicine

Severe Constipation Clinical Gastroenterology and Hepatology

Person-centred maternity care in low-income and middle-income countries: analysis of data from Kenya, Ghana, and India Patience A Afulani, PhD, Beth.

Confessions of a journal junkie

Telling it like it isn't: truth and lies in a post-9/11 world

Thank God for Richard Dawkins?

Low-technology approaches

Volume 393, Issue 10171, Pages e15-e16 (February 2019)

Thank you to our diverse (but not diverse enough) reviewers

Prescription for change

Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study Dr J Michael Wells, MD, Roopan F Farris, MD, Taylor A Gosdin,

Genital herpes—how much of a public-health problem?

Volume 373, Issue 9672, Pages (April 2009)

Matthieu J Guitton The Lancet Planetary Health

Accelerated long-term forgetting in asymptomatic APOE ε4 carriers

Arlene Chan, Marc Buyse, Bin Yao The Lancet Oncology

Steven A Narod The Lancet Volume 349, Issue 9068, (June 1997)

Volume 143, Issue 3, Pages e1 (September 2012)

Spatial lifecourse epidemiology

Clinical haemochromatosis in HFE mutation carriers

Jiayue Hu, George Fu Gao, Ji-Long Chen The Lancet

The effect of social deprivation on clinical outcomes and the use of treatments in the UK cystic fibrosis population: a longitudinal study Dr David C.

Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup:

Political factors behind US global AIDS programmes slow-down

Sputum culture conversion in new TB regimens

Partial restoration of pancreatic function in a child with cystic fibrosis Ciara Howlett, Nicola J Ronan, Muireann NiChroinin, David Mullane, Barry J.

Volume 1, Issue 2, Pages (July 2014)

Deriving a practical framework for the evaluation of health apps

Refining treatment choices for ADHD

Urban trees and asthma: a call for epidemiological research

Fighting for health: meet the doctor-activists

Symptom-based stratification of autoimmune diseases

Sickle cell disease: a new era

Autism, maths, and sex: the special triangle

Presentation transcript:

Pilot evaluation of ivacaftor for chronic bronchitis George M Solomon, Heather Hathorne, Bo Liu, S Vamsee Raju, Ginger Reeves, Edward P Acosta, Mark T Dransfield, Steven M Rowe The Lancet Respiratory Medicine Volume 4, Issue 6, Pages e32-e33 (June 2016) DOI: 10.1016/S2213-2600(16)30047-9 Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure Effect of ivacaftor on functioning of the cystic fibrosis transmembrane conductance regulator and symptoms of chronic bronchitis over the 14 day study period (A) Change in sweat chloride. Horizontal lines represent mean values. (B) Change in nasal potential difference; change induced by chloride-free solution plus isoprenaline. Horizontal lines represent mean values. (C) Change in BCSS score after 14 days of treatment and after a 14 day washout period. Error bars show the standard error of the mean. The range of BCSS is 1–12, and the minimal clinically important difference is 1 unit. BCSS=Breathlessness, Cough, and Sputum Scale. The Lancet Respiratory Medicine 2016 4, e32-e33DOI: (10.1016/S2213-2600(16)30047-9) Copyright © 2016 Elsevier Ltd Terms and Conditions